Trial Outcomes & Findings for Medical Management of Sleep Disturbance During Opioid Tapering (NCT NCT03789214)

Last Updated: 2022-08-08

Results Overview

Area-under-the-curve of self-reported feelings of drug "High" on the morning after study drug administration, measured each morning on a 0-100 point visual analogue scale of the question "Last night, did you feel HIGH?". A score of "0" indicates no abuse liability and a score of 100 indicates extreme abuse liability. This will be assessed over four nights during an opioid taper.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

90 participants

Primary outcome timeframe

4 nights

Results posted on

2022-08-08

Participant Flow

90 individuals were consented and screened (35 did not meet eligibility criteria), 55 were scheduled for admission (7 did not present for admission), 48 were admitted for buprenorphine induction (2 were found to be ineligible at this stage and another 6 left prior to randomization), 40 were randomized (1 left before receiving study drug and 1 was excluded because of uncontrolled precipitated withdrawal), and 38 were included in the analyses of study outcomes.

Participant milestones

Participant milestones
Measure	Placebo Placebo sleep medication (Placebo oral capsule) Placebo oral capsule: Placebo Sleep Medication	Low Dose Suvorexant Low dose sleep medication Low Dose Suvorexant: Low Dose Suvorexant	High Dose Suvorexant High dose sleep medication High Dose Suvorexant: High Dose Suvorexant
Overall Study STARTED	12	14	12
Overall Study COMPLETED	8	9	9
Overall Study NOT COMPLETED	4	5	3

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Medical Management of Sleep Disturbance During Opioid Tapering

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo n=12 Participants Placebo sleep medication (Placebo oral capsule) Placebo oral capsule: Placebo Sleep Medication	Low Dose Suvorexant n=14 Participants Low dose sleep medication Low Dose Suvorexant: Low Dose Suvorexant	High Dose Suvorexant n=12 Participants High dose sleep medication High Dose Suvorexant: High Dose Suvorexant	Total n=38 Participants Total of all reporting groups
Age, Continuous	41.0 years STANDARD_DEVIATION 10.4 • n=5 Participants	36.7 years STANDARD_DEVIATION 9.4 • n=7 Participants	46.3 years STANDARD_DEVIATION 12.7 • n=5 Participants	41.1 years STANDARD_DEVIATION 11.2 • n=4 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	5 Participants n=4 Participants
Sex: Female, Male Male	10 Participants n=5 Participants	13 Participants n=7 Participants	10 Participants n=5 Participants	33 Participants n=4 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Black or African American	6 Participants n=5 Participants	3 Participants n=7 Participants	8 Participants n=5 Participants	17 Participants n=4 Participants
Race (NIH/OMB) White	6 Participants n=5 Participants	10 Participants n=7 Participants	4 Participants n=5 Participants	20 Participants n=4 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants

PRIMARY outcome

Timeframe: 4 nights

Population: Participants who completed the buprenorphine taper. 1 participant dropped out of the high dose suvorexant condition.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Placebo sleep medication (Placebo oral capsule) Placebo oral capsule: Placebo Sleep Medication	Low Dose Suvorexant n=14 Participants Low dose sleep medication Low Dose Suvorexant: Low Dose Suvorexant	High Dose Suvorexant n=11 Participants High dose sleep medication High Dose Suvorexant: High Dose Suvorexant
Abuse Liability as Assessed by Visual Analogue Scale	23.9 score on a scale*days Standard Deviation 33.5	20.9 score on a scale*days Standard Deviation 28.7	22.8 score on a scale*days Standard Deviation 31.0

PRIMARY outcome

Timeframe: Four nights during a buprenorphine taper

Population: Participants who completed the buprenorphine taper. 1 participant dropped out of the high dose suvorexant condition.

Area-under-the-curve scores of total number of minutes slept per night as measured by a 3-lead wireless electroencephalography and wrist worn actigraphy.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Placebo sleep medication (Placebo oral capsule) Placebo oral capsule: Placebo Sleep Medication	Low Dose Suvorexant n=14 Participants Low dose sleep medication Low Dose Suvorexant: Low Dose Suvorexant	High Dose Suvorexant n=11 Participants High dose sleep medication High Dose Suvorexant: High Dose Suvorexant
Total Sleep Time During Buprenorphine Taper	891.6 minutes*nights Standard Deviation 287.9	1183.6 minutes*nights Standard Deviation 300.1	1098.4 minutes*nights Standard Deviation 287.3

PRIMARY outcome

Timeframe: Four nights following buprenorphine discontinuation

Population: Prior to completion of the post-taper phase, 4 participants dropped out from the placebo condition, 5 dropped out from the low-dose suvorexant condition, and 3 dropped out from the high-dose suvorexant condition.

Area-under-the-curve scores of total number of minutes slept per night as measured by a 3-lead wireless electroencephalography and wrist worn actigraphy.

Outcome measures

Outcome measures
Measure	Placebo n=8 Participants Placebo sleep medication (Placebo oral capsule) Placebo oral capsule: Placebo Sleep Medication	Low Dose Suvorexant n=9 Participants Low dose sleep medication Low Dose Suvorexant: Low Dose Suvorexant	High Dose Suvorexant n=9 Participants High dose sleep medication High Dose Suvorexant: High Dose Suvorexant
Total Sleep Time During Post-taper	1049.3 minutes*nights Standard Deviation 253.6	1113.2 minutes*nights Standard Deviation 342.1	1055.9 minutes*nights Standard Deviation 274.5

PRIMARY outcome

Timeframe: Three days during a buprenorphine taper

Population: Participants who completed the buprenorphine taper. 1 participant dropped out of the high dose suvorexant condition.

Area-under-the-curve of peak daily scores on the Subjective Opiate Withdrawal Scale (SOWS) (a 16-item self-reported scale that measures individual opioid withdrawal symptoms using a 0-4 Likert scale; total range of SOWS is 0-64; lower scores indicate mild opioid withdrawal relative to higher scores which indicate more severe opioid withdrawal).

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Placebo sleep medication (Placebo oral capsule) Placebo oral capsule: Placebo Sleep Medication	Low Dose Suvorexant n=14 Participants Low dose sleep medication Low Dose Suvorexant: Low Dose Suvorexant	High Dose Suvorexant n=11 Participants High dose sleep medication High Dose Suvorexant: High Dose Suvorexant
Subjective Opiate Withdrawal Scale During Buprenorphine Taper	15.5 score on a scale*days Standard Deviation 12.0	10.8 score on a scale*days Standard Deviation 15.1	14.8 score on a scale*days Standard Deviation 11.2

PRIMARY outcome

Timeframe: Three days following buprenorphine discontinuation

Outcome measures

Outcome measures
Measure	Placebo n=8 Participants Placebo sleep medication (Placebo oral capsule) Placebo oral capsule: Placebo Sleep Medication	Low Dose Suvorexant n=9 Participants Low dose sleep medication Low Dose Suvorexant: Low Dose Suvorexant	High Dose Suvorexant n=9 Participants High dose sleep medication High Dose Suvorexant: High Dose Suvorexant
Subjective Opiate Withdrawal Scale During Post-taper	17.9 score on a scale*days Standard Deviation 15.1	9.0 score on a scale*days Standard Deviation 9.8	6.4 score on a scale*days Standard Deviation 3.9

Adverse Events

Placebo

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Low Dose Suvorexant

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

High Dose Suvorexant

Serious events: 0 serious events

Other events: 7 other events

Deaths: 0 deaths

Pre-randomization

Serious events: 0 serious events

Other events: 10 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Additional Information

Andrew S. Huhn, Ph.D.

The Johns Hopkins University School of Medicine

Phone: 410-550-1971

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Other adverse events
Measure	Placebo n=12 participants at risk Placebo sleep medication (Placebo oral capsule) Placebo oral capsule: Placebo Sleep Medication	Low Dose Suvorexant n=14 participants at risk Low dose sleep medication Low Dose Suvorexant: Low Dose Suvorexant	High Dose Suvorexant n=12 participants at risk High dose sleep medication High Dose Suvorexant: High Dose Suvorexant	Pre-randomization n=38 participants at risk Pre-randomization to Suvorexant or placebo groups
General disorders Headache	50.0% 6/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	21.4% 3/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	16.7% 2/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	13.2% 5/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Gastrointestinal disorders Abdominal Cramp	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	7.9% 3/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Gastrointestinal disorders Abdominal Distention	25.0% 3/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	10.5% 4/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Gastrointestinal disorders Abdominal Pain	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Gastrointestinal disorders Constipation	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	14.3% 2/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	5.3% 2/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Gastrointestinal disorders Indigestion	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	10.5% 4/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Reproductive system and breast disorders Prolonged Erection	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	7.1% 1/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Psychiatric disorders Agitation	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Psychiatric disorders Anxiety	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	2.6% 1/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Nervous system disorders Confusion	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	14.3% 2/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Nervous system disorders Dizziness	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Nervous system disorders Dream Abnormal	33.3% 4/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	14.3% 2/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	25.0% 3/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Nervous system disorders Drowsiness	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	7.1% 1/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	16.7% 2/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	2.6% 1/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Nervous system disorders Euphoria	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	14.3% 2/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Nervous system disorders Impaired/Groggy	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	14.3% 2/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Cardiac disorders Hypertension	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	2.6% 1/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Cardiac disorders Tachycardia	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	2.6% 1/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
General disorders Appetite Decreased	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	2.6% 1/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
General disorders Appetite Increased	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	2.6% 1/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Gastrointestinal disorders Diarrhea	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	5.3% 2/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Gastrointestinal disorders Dyspensia	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	2.6% 1/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Gastrointestinal disorders Flatulance	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	5.3% 2/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Gastrointestinal disorders Nausea	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	10.5% 4/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	2.6% 1/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Musculoskeletal and connective tissue disorders Pain Lower Extremity	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	2.6% 1/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Nervous system disorders Insomnia	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Psychiatric disorders Irritability	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Nervous system disorders Light headed	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	5.3% 2/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Nervous system disorders Tremor	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Nervous system disorders Stuttering/Fluency Disorder	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	2.6% 1/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Eye disorders Photophobia	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	14.3% 2/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Skin and subcutaneous tissue disorders Pruritus	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Skin and subcutaneous tissue disorders Sweat Increased	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Eye disorders Blurred Vision	8.3% 1/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Skin and subcutaneous tissue disorders Itchy Eyes	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	2.6% 1/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.
Eye disorders Eye Pain	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/14 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	0.00% 0/12 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.	2.6% 1/38 • 11 days of residential treatment and 5-10 days of follow-up (16-21 days total). Adverse events represent all events rated as "possibly, probably, or definitely" related to study participation before and after study drug (suvorexant or placebo) administration. All participants received buprenorphine/naloxone for three days prior to randomization, and adverse events in this section may represent events that occurred prior to study drug administration but within the 11 day experimental period because some events persisted across study phases.